Skip to main
BIIB
BIIB logo

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 21%
Hold 42%
Sell 5%
Strong Sell 0%

Bulls say

Biogen has experienced a notable 35% increase in stock value since the beginning of the third quarter of 2025, in line with a broader rally in the biopharma sector, indicating a positive market sentiment towards the company. The successful execution of commercial strategies for new product launches, particularly Leqembi, Skyclaris, and Zurzuvae, has resulted in revenue contributions that exceed consensus expectations, providing optimism for the company's near-term earnings potential. With revenue generation forecasts suggesting that key product launches could contribute $2.5 to $3.0 billion by 2030, Biogen is well-positioned for future growth driven by its evolving pipeline and strategic business development initiatives, despite the challenges posed by its declining multiple sclerosis franchise.

Bears say

Biogen's financial outlook is negatively influenced by anticipated declines in its multiple sclerosis (MS) franchise, which is projected to face intensified competition from upcoming biosimilars, leading to an estimated 5-8% decrease in global MS revenues in the second half of 2025. The company's revenue growth is expected to remain largely flat with a compound annual growth rate (CAGR) of nearly zero from 2026 to 2030, primarily due to erosion in the MS business and decreasing royalties from Ocrevus starting in 2029. Additionally, pressure on other product lines, such as Skyclarys, alongside elevated difficulties in clinical trials for lupus treatments, further exacerbates concerns regarding Biogen's long-term profitability and growth prospects.

Biogen (BIIB) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 21% recommend Buy, 42% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 19 analysts, Biogen (BIIB) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $180.68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $180.68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.